11.74
price up icon3.62%   0.41
after-market Handel nachbörslich: 11.75 0.010 +0.09%
loading
Schlusskurs vom Vortag:
$11.33
Offen:
$11.24
24-Stunden-Volumen:
1.96M
Relative Volume:
0.81
Marktkapitalisierung:
$3.48B
Einnahmen:
$423.49M
Nettoeinkommen (Verlust:
$-147.07M
KGV:
-18.34
EPS:
-0.64
Netto-Cashflow:
$-88.03M
1W Leistung:
+2.18%
1M Leistung:
+10.75%
6M Leistung:
+12.88%
1J Leistung:
+1.38%
1-Tages-Spanne:
Value
$11.21
$11.75
1-Wochen-Bereich:
Value
$11.21
$11.75
52-Wochen-Spanne:
Value
$9.02
$14.57

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name
Firmenname
Amicus Therapeutics Inc
Name
Telefon
(215) 921-7600
Name
Adresse
3675 MARKET STREET, PHILADELPHIA, NJ
Name
Mitarbeiter
517
Name
Twitter
@amicusrx1
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
FOLD's Discussions on Twitter

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-06 Eingeleitet Jefferies Buy
2024-05-30 Eingeleitet Wells Fargo Overweight
2024-05-14 Hochstufung Guggenheim Neutral → Buy
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-09-09 Eingeleitet Morgan Stanley Equal-Weight
2022-04-13 Fortgesetzt Goldman Neutral
2022-01-14 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-11-15 Hochstufung Stifel Hold → Buy
2021-09-30 Hochstufung JP Morgan Neutral → Overweight
2021-07-19 Fortgesetzt BTIG Research Buy
2021-05-27 Eingeleitet Needham Hold
2021-05-21 Eingeleitet UBS Buy
2021-04-14 Hochstufung Cantor Fitzgerald Neutral → Overweight
2021-03-02 Eingeleitet Stifel Hold
2021-02-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-02-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-28 Fortgesetzt Cantor Fitzgerald Overweight
2020-12-10 Herabstufung Citigroup Buy → Neutral
2020-11-11 Eingeleitet Berenberg Hold
2020-06-17 Eingeleitet BTIG Research Buy
2020-02-04 Fortgesetzt Cantor Fitzgerald Overweight
2019-11-12 Bestätigt H.C. Wainwright Buy
2019-06-17 Eingeleitet H.C. Wainwright Buy
2019-06-05 Bestätigt Cantor Fitzgerald Overweight
2019-04-05 Eingeleitet Janney Buy
2019-01-30 Eingeleitet Cantor Fitzgerald Overweight
2018-10-29 Eingeleitet Citigroup Neutral
2018-08-17 Herabstufung Chardan Capital Markets Buy → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
2017-09-13 Bestätigt Chardan Capital Markets Buy
2017-08-10 Bestätigt Chardan Capital Markets Buy
2017-01-24 Hochstufung Robert W. Baird Neutral → Outperform
2016-05-18 Eingeleitet BofA/Merrill Buy
2016-04-14 Eingeleitet Robert W. Baird Neutral
2016-04-12 Bestätigt Chardan Capital Markets Buy
2015-09-16 Herabstufung Chardan Capital Markets Buy → Neutral
2015-06-16 Bestätigt Chardan Capital Markets Buy
Alle ansehen

Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten

pulisher
12:08 PM

Amicus Therapeutics Q3 2024 Earnings Preview - MSN

12:08 PM
pulisher
05:36 AM

Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

05:36 AM
pulisher
Nov 04, 2024

Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire

Oct 28, 2024
pulisher
Oct 26, 2024

Assenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance

Oct 25, 2024
pulisher
Oct 23, 2024

Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

Pompe Disease Market on Track for Major Expansion by 2034, - openPR

Oct 22, 2024
pulisher
Oct 22, 2024

Pompe Disease Market on Track for Major Expansion by 2034, According to DelveInsight | Asklepios Biopharma, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark - The Globe and Mail

Oct 22, 2024
pulisher
Oct 21, 2024

(FOLD) Proactive Strategies - Stock Traders Daily

Oct 21, 2024
pulisher
Oct 21, 2024

Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Oct 21, 2024
pulisher
Oct 21, 2024

Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of America - Defense World

Oct 21, 2024
pulisher
Oct 19, 2024

How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Creative Planning Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Oct 19, 2024
pulisher
Oct 19, 2024

What is Zacks Research’s Estimate for FOLD Q3 Earnings? - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

Teva settles patent litigation with Amicus (TEVA:NYSE) - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

Zacks Research Issues Optimistic Outlook for FOLD Earnings - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

What is Zacks Research’s Estimate for FOLD Q2 Earnings? - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva - GlobeNewswire

Oct 17, 2024
pulisher
Oct 17, 2024

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU - Benzinga

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpHere's Why - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus announces settlement of Galafold patent litigation with Teva - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics settles patent litigation with Teva - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics settles patent litigation with Teva By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics Shares Rise After Lawsuit Settlement, Deal With Teva - MarketWatch

Oct 17, 2024
pulisher
Oct 17, 2024

Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research Forecasts - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Oct 16, 2024
pulisher
Oct 15, 2024

Taking on analysts’ expectations and winning: Amicus Therapeutics Inc (FOLD) - SETE News

Oct 15, 2024
pulisher
Oct 15, 2024

Morgan Stanley Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $18.00 - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Amicus Therapeutics (NASDAQ:FOLD) Cut to Hold at StockNews.com - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Gaucher’s Disease Treatment Industry to Witness an Outstanding Growth by 2034 |Amicus Therapeutics, Inc., Novartis AG, S – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

Analyzing Amicus Therapeutics Inc (FOLD) After Recent Trading Activity - Knox Daily

Oct 14, 2024

Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):